

Imprimis Pharmaceuticals Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 11-Dec-2012

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 8

Product Portfolio Drugs..... 10

[Return to Table of Contents](#)

Imprimis Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Imprimis Pharmaceuticals Inc
Parent Company Name	Imprimis Pharmaceuticals Inc
Website	http://www.transdelpharma.com
Country	US
Number of Drugs in Active Development	1
Number of Inactive Drugs	0
Number of Patents as Owner	0
Number of Patents as Third Party	0
Number of Deals	8
Key Indications	Pain
Key Target-based Actions	Cyclooxygenase inhibitor
Key Technologies	Dermatological formulation, Emulsion dermatological, Small molecule therapeutic, Transdermal formulation

COMPANY PROFILE

SUMMARY

Imprimis Pharmaceuticals Inc (formerly Transdel Pharmaceuticals) aims to develop and commercialize non-invasive topical therapeutics. In January 2009, the company planned to expand its business to include topical cosmetics and cosmeceuticals.

In February 2011, the company was considering strategic options such as partnering or collaboration agreements, a merger, equity or debt financing or sale of the company, in order to increase shareholder value and continue development of TDLP-110. The company was consulting two investment banks regarding the strategic alternatives. In June 2011, Cardium Therapeutics agreed to acquire all of Transdel's business assets under Chapter 11 of the US Bankruptcy Code for up to \$4 million. By April 2012, the company had changed its name to Imprimis Pharmaceuticals.

ACQUISITIONS AND SPIN-OFFS

In June 2011, Cardium Therapeutics agreed to acquire all of Transdel's business assets under Chapter 11 of the US Bankruptcy Code for up to \$4 million. The deal would include Transdel's topical analgesic, TDLP-110, and royalty-bearing license agreements from the company's cosmeceutical business. The \$4 million would be paid in unregistered Cardium shares priced at a minimum of \$0.50 per share with \$1 million being a contingent value payment to be held in escrow (for five years) pending FDA approval of TDLP-110. Transdel's Ketotransdel and related drug delivery technology assets would be managed by a new wholly owned subsidiary of Cardium whereas its cosmeceutical operations would be transferred to Cardium's MedPodium division. At that time, the transaction was subject to approval by the bankruptcy court. By July 2011, the companies had requested the bankruptcy court approve the sale under Section 363 which would avoid filing a plan subject to approval by creditors and in support of this Transdel's major creditor filed a declaration in favor of the purchase. However, later in July 2011, the creditor opposed the sale, potentially to offer a plan of its own, leading to denial of approval by the court. At that time, Cardium planned to continue to assess its options regarding the acquisition and other business opportunities under consideration. By April 2012, the company had changed its name to Imprimis Pharmaceuticals and received financing. At that time, it was presumed the proposed acquisition had been terminated.

In October 2007, Transdel completed a merger and began trading under 'TDLP' on the OTC Bulletin Board.

LICENSING AGREEMENTS

In June 2009, JH Direct acquired the exclusive worldwide rights to Transdel Pharmaceuticals' anti-cellulite cosmeceutical product which uses Transdel's transdermal delivery system technology, Transdel. Transdel would receive initial royalty advances and a continuing licensing royalty on the worldwide sales.

[Return to Table of Contents](#)



FINANCIAL

In April 2012, Imprimis raised net proceeds of approximately \$7.95 million in a private placement of stock and three year warrants. Each unit was priced \$0.79 and consisted of one share of common stock and a 25% warrant, to purchase additional common shares of Imprimis at \$1.185 per share. Also, the company had the unilateral right to call for the mandatory exercise of the warrants with 90 days notice to the holders, following Impracor approval. At that time, the company intended to file an application to NASDAQ 'in the coming months', for the listing of its shares.

In April 2010, Transdel raised \$1 million from a private debt financing. The company issued a 2-year senior convertible promissory note with an annual interest rate of 7.5%.

In May 2008, Transdel raised \$4 million from closing a private placement of 1,818,180 shares priced at \$2.20 each and warrants to buy 227,272 shares for \$4.40 or \$5.50 each.

In September 2007, the company raised \$4 million from a stock sale.


In June 2007, the company raised \$1.5 million from a note sale.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	1	0	0	0	1
Drug - Manufacturing/Supply	0	0	1	0	1
Drug - Development Services	0	0	3	0	3
Technology - Delivery/Formulation	3	0	0	0	3

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	0	2

[Return to Table of Contents](#)

Trials by Phase

Phase	Ongoing	All
Phase 3	0	2
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

ketoprofen (topical cream, pain), Imprimis

Drug Name	ketoprofen (topical cream, pain), Imprimis
Key Synonyms	ketoprofen, Ketotransdel, Impracor
Originator Company	Imprimis Pharmaceuticals Inc
Active Companies	Imprimis Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Pain
Target-based Actions	Cyclooxygenase inhibitor
Other Actions	Leukotriene synthesis inhibitor, Analgesic, Non-steroidal anti-inflammatory, PG synthesis inhibitor
Technologies	Transdermal formulation, Dermatological formulation, Emulsion dermatological, Small molecule therapeutic
Last Change Date	20-Sep-2012

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

